Almost £1 billion of taxpayers’ money has been wasted on an anti-Covid drug that does not work, The Telegraph can disclose.
Less than two per cent of the 2.23 million courses of the antiviral drug molnupiravir procured by the Department of Health have ever been prescribed to patients, analysis by The Telegraph shows.
The rest are unlikely to ever be used after research found the drug makes no difference to hospitalisation or death rates.
The National Institute for Health and Care Excellence (Nice), the UK drugs watchdog, recently said molnupiravir should not be routinely used. In November, the drug was added to its draft “not recommended” list for treatment
An NHS whistleblower, who wishes to remain anonymous, has come forward with allegations that the NHS hospitals were not overwhelmed during the Covid-19 pandemic, as was reported by authorities and the mainstream media.
The whistleblower also confirmed that the little care given throughout the pandemic amounted to negligence, and that the Goverment and NHS bosses essentially instructed staff to let people die, or in some cases kill them through the ‘End of Life Care’ programme and falsely label the deaths as being due to Covid-19.
Up to 100 times more may have been spent on preventing each Covid death than on preventing each non-Covid death
This guideline was developed before the COVID-19 pandemic. It covers diagnosing and managing pneumonia in adults who do not have COVID-19. It aims to improve accurate assessment and diagnosis of pneumonia to help guide antibiotic prescribing and ensure that people receive the right treatment.
July 2022: We reinstated this guideline, which was temporarily withdrawn in May 2020 because of the COVID-19 pandemic, and plan to update it.
The cost of adding one more year of life to someone who is dying of coronavirus is more than five times higher than the maximum the NHS can spend on other illnesses, according to a statistician.
- The cost of adding one more year of life to someone who is dying of coronavirus is more than five times higher than the maximum the NHS can spend on other illnesses.
- Professor Simon Wood has calculated that it costs approximately £180,000 per extra year of life to rescue a dying Covid-19 patient.
- NHS watchdog will only spend up to £30,000 per year of life on any new treatment, deeming any higher cost a bad cost-to-benefit ratio.
- Many people left in worse physical or mental health, or in poverty, as a result of policies brought in to slow down Covid-19 could see years chopped off their life expectancy.
- The Office for Budget Responsibility predicted the UK’s national debt would grow by £550billion next year as a result of spending during the epidemic.
- The National Institute for Health and Care Excellence (NICE), which makes decisions on which drugs are good value for the NHS, considers £30,000 to be at the upper end of its good value limit.
- Statistical organisations across the UK, meanwhile, suggest that there have been around 59,000 ‘excess deaths’ during the epidemic, which includes people who died of Covid-19 but never tested positive, as well as those who died because of indirect effects of lockdown, such as being unable to get hospital care.